CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer

Jong Ho Cho, Wei Zhou, Yoon-La Choi, Jong-Mu Sun, Hyejoo Choi, Tae-Eun Kim, Marisa Dolled-Filhart, Kenneth Emancipator, Mary Anne Rutkowski, Jhingook Kim

Cancer Research and Treatment. 2018;50(1):95-102. Published online 2017 March 17 DOI: https://doi.org/10.4143/crt.2016.591

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer

Jong Ho Cho, Wei Zhou, Yoon-La Choi, Jong-Mu Sun, Hyejoo Choi, Tae-Eun Kim, Marisa Dolled-Filhart, Kenneth Emancipator, Mary Anne Rutkowski, Jhingook Kim

Cancer Research and Treatment. 2018;50(1):95-102

Link1

Link2 Link3

MYC expression correlates with PD-L1 expression in non-small cell lung cancer

Eun Young Kim, Arum Kim, Se Kyu Kim, Yoon Soo Chang

Lung Cancer. 2017;110:63-67

Link1 Link2

The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy

LC Villaruz, MA Socinski

Clinical Pharmacology & Therapeutics. 2016;100(3):212-214

Link1

13 EGFR-mutation analysis, treatment and outcomes in newly diagnosed patients with non-small cell lung cancer (NSCLC): a single-institution retrospective review

D. Enting, A. Januszewski, T. Benepal

Lung Cancer. 2012;75:S5

Link1 Link2

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Young Kwang Chae, Alan Pan, Andrew A. Davis, Kirtee Raparia, Nisha A. Mohindra, Maria Matsangou, Francis J. Giles

Clinical Lung Cancer. 2016;17(5):350-361

Link1 Link2

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer

Kazuhiko Shien, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba

Lung Cancer. 2016;99:79-87

Link1 Link2

Association of PD-1 , PD-L1 , and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non–Small-Cell Lung Cancer

Aránzazu Lafuente-Sanchis, Ángel Zúñiga, Miriam Estors, Néstor J. Martínez-Hernández, Antonio Cremades, María Cuenca, José M. Galbis

Clinical Lung Cancer. 2017;18(2):e109-e116

Link1 Link2

PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors

Tarek M. Meniawy, Richard A. Lake, Alison M. McDonnell, Michael J. Millward, Anna K. Nowak

Lung Cancer. 2016;93:9-16

Link1 Link2

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors

Jéssica Gomes, Marcelo Cruz

OncoTargets and Therapy. 2015;1137

Link1

168: PD-RAD: A translational study investigating PD-L1 expression after radiotherapy for non-small cell lung cancer (NSCLC)

T. Kordbacheh, C. Chan, C. Faivre-Finn, K. Franks, F. McDonald, M. Forster, R. Mendes, S. Quezada, S. Dovedi, C. Ralph, S. Popat, K. Harrington, A. Melcher, A. Popple, T. Illidge

Lung Cancer. 2017;103:S78-S79

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.